Search research articles
Contact Us
Filters
Showing results (71-80 of 84) with videos related to
Page
of 9
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 23, 2025
A Generalized Risk Adjusted Cost Effectiveness (GRACE) Economic Model for Measuring the Value of Interventions that Delay Mobility Impairment Across Neurological Conditions
Jason Shafrin, Jaehong Kim, Jacob Fajnor, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 18, 2017
Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework
Darius N Lakdawalla, Jason Shafrin, Ningqi Hou, et al.
Journal of Medical Economics
|
November 26, 2025
Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States
Jason Shafrin, Kejal Jadhav, Cheryl Warren, et al.
Patient Preference and Adherence
|
July 20, 2017
Access to credible information on schizophrenia patients' medication adherence by prescribers can change their treatment strategies: evidence from an online survey of providers
Jason Shafrin, Suepattra G May, Anshu Shrestha, et al.
Antimicrobial Resistance and Infection Control
|
June 14, 2022
Economic burden of antibiotic-not-susceptible isolates in uncomplicated urinary tract infection: Analysis of a US integrated delivery network database
Jason Shafrin, Alen Marijam, Ashish V Joshi, et al.
Antimicrobial Resistance and Infection Control
|
November 5, 2022
Impact of suboptimal or inappropriate treatment on healthcare resource use and cost among patients with uncomplicated urinary tract infection: an analysis of integrated delivery network electronic health records
Jason Shafrin, Alen Marijam, Ashish V Joshi, et al.
Annals of the American Thoracic Society
|
August 23, 2024
Economic Value of Bronchoscopy Technologies that Improves Sensitivity for Malignancy for Peripheral Pulmonary Lesions
David E Ost, Fabien Maldonado, Jason Shafrin, et al.
Future Oncology (London, England)
|
February 27, 2026
Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US
Tara Graff, Savreet Bains Chawla, Monika Jun, et al.
Journal of Managed Care & Specialty Pharmacy
|
August 24, 2022
Health care utilization and costs associated with functional status in patients with psoriatic arthritis
Alexis Ogdie, Mark Hwang, Phani Veeranki, et al.
Current Medical Research and Opinion
|
March 9, 2021
The impact of vaso-occlusive crises and disease severity on quality of life and productivity among patients with sickle cell disease in the US
Jason Shafrin, Howard H Z Thom, Edna Keeney, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 84) with videos related to
Sort By:
Page
of 9
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 23, 2025
A Generalized Risk Adjusted Cost Effectiveness (GRACE) Economic Model for Measuring the Value of Interventions that Delay Mobility Impairment Across Neurological Conditions
Jason Shafrin, Jaehong Kim, Jacob Fajnor, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 18, 2017
Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework
Darius N Lakdawalla, Jason Shafrin, Ningqi Hou, et al.
Journal of Medical Economics
|
November 26, 2025
Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States
Jason Shafrin, Kejal Jadhav, Cheryl Warren, et al.
Patient Preference and Adherence
|
July 20, 2017
Access to credible information on schizophrenia patients' medication adherence by prescribers can change their treatment strategies: evidence from an online survey of providers
Jason Shafrin, Suepattra G May, Anshu Shrestha, et al.
Antimicrobial Resistance and Infection Control
|
June 14, 2022
Economic burden of antibiotic-not-susceptible isolates in uncomplicated urinary tract infection: Analysis of a US integrated delivery network database
Jason Shafrin, Alen Marijam, Ashish V Joshi, et al.
Antimicrobial Resistance and Infection Control
|
November 5, 2022
Impact of suboptimal or inappropriate treatment on healthcare resource use and cost among patients with uncomplicated urinary tract infection: an analysis of integrated delivery network electronic health records
Jason Shafrin, Alen Marijam, Ashish V Joshi, et al.
Annals of the American Thoracic Society
|
August 23, 2024
Economic Value of Bronchoscopy Technologies that Improves Sensitivity for Malignancy for Peripheral Pulmonary Lesions
David E Ost, Fabien Maldonado, Jason Shafrin, et al.
Future Oncology (London, England)
|
February 27, 2026
Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US
Tara Graff, Savreet Bains Chawla, Monika Jun, et al.
Journal of Managed Care & Specialty Pharmacy
|
August 24, 2022
Health care utilization and costs associated with functional status in patients with psoriatic arthritis
Alexis Ogdie, Mark Hwang, Phani Veeranki, et al.
Current Medical Research and Opinion
|
March 9, 2021
The impact of vaso-occlusive crises and disease severity on quality of life and productivity among patients with sickle cell disease in the US
Jason Shafrin, Howard H Z Thom, Edna Keeney, et al.
Page
of 9